2548 research outputs found
Sort by
Understanding Stress-induced Alterations in Microglia Density in the Medial Prefrontal Cortex of Male and Female S1PR3GR-/GR- Rats
Get PDFUnderstanding Vaccine Hesitancy: An Analysis of Caregiver Influences on Pediatric COVID-19 Vaccination Decisions
Get PDF
Barriers to Follow-up Adherence for Patients with Juvenile Idiopathic Arthritis Associated Uveitis at a Tertiary Care Center
Get PDFHaemophilus parainfluenza-Associated Aortic Root Abscess and Septic Embolic Stroke Post-transcatheter Aortic Valve Replacement: A Case Study.
No full textWe present a rare instance of aortic root abscess and septic embolic stroke due to Haemophilus parainfluenza in a 75-year-old male patient who had undergone a recent transcatheter aortic valve replacement. The patient initially presented with generalized weakness and altered mental status. Blood cultures grew Haemophilus parainfluenza. Brain imaging showed multiple infarcts with some areas of hemorrhagic conversion. Echocardiography demonstrated an aortic root abscess as well as vegetation on the tricuspid valve. Surgical correction was deemed high risk; hence, management involved intravenous (IV) antibiotics, resulting in the resolution of both symptoms and the absces
COVID-19 Coagulopathy.
No full textCoronavirus disease of 2019 (COVID-19) is the respiratory viral infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite being a primary respiratory illness, it is commonly complicated by systemic involvement of the vasculature leading to arterial and venous thrombosis. In this review, we will focus on the association between COVID-19 and thrombosis. We will highlight the pathophysiology of COVID-19 coagulopathy. The clinical manifestations of COVID-19 vasculopathy will be discussed with a focus on venous and arterial thromboembolic events. COVID-19 vasculopathy and disseminated intravascular coagulation (DIC) are distinguished within, as well as areas of controversy, such as long COVID . Finally, the current professional guidelines on prevention and treatment of thrombosis associated with SARS-CoV-2 infection will be discussed
A Brief Review of Zuranolone
Get PDFZuranolone, a novel analog of allopregnanolone, has been approved by the U.S. Food and Drug Administration (FDA) as the first oral medication approved for the treatment of postpartum depression in adults. Developed by Sage Therapeutics under the brand name Zurzuvae, zuranolone was approved by the FDA on August 4th, 2023.1 Zuranolone is a modified version of brexanolone (sold under the brand name Zulpresso), an intravenously administered allopregnanolone formulation that was previously the only FDA-approved medication for postpartum depression. Zuranolone offers a more accessible treatment option for patients with efficacy established in clinical trials. Its approval expands the treatment landscape for depression, especially in the peripartum period, and marks a crucial step forward in psychopharmacological innovation
Evaluating Mental Health and Rates of Hospitalization in Adolescents with Sickle Cell Disease
Get PDFAutoimmune hemolytic anemia: a rare presentation of mantle cell lymphoma
Get PDFAutoimmune hemolytic anemia (AIHA) is a well-recognized phenomenon of non-Hodgkin lymphoma, albeit with only few cases described with mantle cell lymphoma (MCL). The characteristics of such cases can improve understanding and management of AIHA in this type of lymphoma. To that end, we describe herein two cases of patients with MCL who presented with AIHA, with comparison to nine previously described cases in literature
Navigating Narrow Paths, Efficacy & Safety of Endoscopic Stricturotomy in Inflammatory Bowel Disease Patients: A Systematic Review & Meta-Analysis
No full textInstitutions: Saint Peter\u27s University Hospital, USA; Shree Bhausaheb Hire Government Medical College, India; Reading Hospital, USA; The University of Texas Health Science Center at San Antonio, USA; University of Connecticut, USA; Rochester General Health System, USA; East Tennessee State University, USA; Centura Health at Home, USA; Orlando Gastroenterology PA, USA. Disclosure compliance: I understand. Participant disclosure: Vishali Moond: NO financial relationship with a commercial interest; Archit Garg: NO financial relationship with a commercial interest; Ameya Kasture: NO financial relationship with a commercial interest; Priyadarshini Loganathan: NO financial relationship with a commercial interest; Ruchir Paladiya: NO financial relationship with a commercial interest; Sheza Malik: NO financial relationship with a commercial interest; Sandesh Parajuli: NO financial relationship with a commercial interest; Hassam Ali: NO financial relationship with a commercial interest; Arkady Broder: NO financial relationship with a commercial interest; Babu Mohan: NO financial relationship with a commercial interest; Douglas Adler: Consulting: Boston Scientific, Olympus; Speaking and Teaching: Abbvie. Background & Aims: Endoscopy stricturotomy has gathered attention in the treatment of strictures in patients with inflammatory bowel disease (IBD) and seems to be a promising novel approach. However, the clinical outcomes of endoscopic strictuorotomy have not been well-established due to small-sized studies. We performed a pooled analysis of the efficacy and safety of endoscopic stricturotomy in patients with IBD. Methods: We searched multiple electronic databases including Medline, Web of Science, CochranePubmed, and Embase and conference proceedings from inception through October 2023 articles reporting outcomes following endoscopic stricturotomy for benign lower gastrointestinal stricturing disease. Two reviewers independently conducted screening, full-text review, and data extraction according to PRISMA guidelines. The clinical outcomes studied were pooled technical success, clinical success and adverse events. Standard meta-analysis methods were employed using the random-effects model, and heterogeneity was studied by I2 statistics. Results: We analyzed 18 studies including 4 prospective and 14 retrospective studies involving 637 patients (363 males with a mean age of 45 years) and a mean duration follow-up of 574 days. 53% of these patients had Crohn\u27s disease with 85.6% having anastomotic strictures located mostly in the ileocolonic region (26.58%). The median length of the strictures was 1.80 cm. The pooled technical success rate of endoscopic stricturotomy was 95.7 % (CI 92.7 - 97.5%; I2 =0%) and the pooled therapeutic success rate was 67.4% (CI 49.9 - 81.1%; I2 = 72.7%). The pooled major complications per procedure were 5.5% (4.2-7.2%; I2 =0%). The risk of bleeding associated per procedure was 4.8% (3.6-6.5%; I2 =0%, ) whereas the risk of perforation associated per procedure was 1.9% (1.1-3.3%; I2 =0%). There were no reported deaths with endoscopic stricturotomy. We found that the pooled rate of patients who required repeat stricturotomy was 39.9% (11.6 -75.8%; I2 =91.8%) whereas the pooled rate of patients who required repeat surgery was 16.7% (7.5 -33.1%; I2 =87%). Conclusions: On meta-analysis, endoscopic stricturotomy demonstrated an excellent pooled technical success rate of 95.7%. However, the pooled clinical success was modest at 67.4%. Pooled adverse events suggest that the procedure is safe with a low risk of perforation at 1.9%. Overall, the results of this analysis seem in favour of endoscopic stricturotomy in patients with IBD. However, in light of modest clinical success and 39.9% of patients requiring repeat stricturotomies, future studies are warranted to ascertain the right patient cohort that would benefit the most